Angiogenic gene therapy in cardiovascular diseases: dream or vision? - Wikidata - awgldk - TriplyDB

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

http://www.wikidata.org/entity/Q45863499

about

Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling Cardiovascular Gene Therapy: Past, Present, and Future.PET imaging in heart failure: the role of new tracers.Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up.MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target.Myocardial perfusion in patients with non-ischaemic systolic heart failure and type 2 diabetes: a cross-sectional study using Rubidium-82 PET/CT.Doxycycline modulates VEGF-A expression: Failure of doxycycline-inducible lentivirus shRNA vector to knockdown VEGF-A expression in transgenic mice.Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option.Optimizing Cardiac Delivery of Modified mRNA.Temporal Dynamics of Gene Expression During Endothelial Cell Differentiation From Human iPS Cells: A Comparison Study of Signalling Factors and Small Molecules.EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF.Myocardial infarction stabilization by cell-based expression of controlled Vascular Endothelial Growth Factor levels.Quantification of myocardial infarct area based on TRAFFn relaxation time maps - comparison with cardiovascular magnetic resonance late gadolinium enhancement, T1ρ and T2 in vivo.Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology Human Vascular Endothelial Growth Factor A Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration

P2860

Q33911723-80019FA2-CDFD-421C-9D53-B3E31CE519E6 Q38733395-B38FA216-09A0-4678-9DAF-53C59756DC4B Q39285234-B12A41E2-1C38-4FA8-B9B0-A4CC69318C65 Q45252610-3FE8FEE1-BF71-455E-80A9-1603626368FC Q45875338-907E3B66-F464-4485-B29E-90E824BF29B8 Q47559357-A7B22458-E42E-4F76-9485-F0D4D82A70A6 Q47851682-DFFA6ECD-2911-4504-9A69-B3B745097191 Q49561459-24563153-DF44-4FF8-B5D7-0446D6791185 Q50445673-F826546E-EF3A-47D5-A02D-15547EA762B9 Q52624116-5A0BDEB4-B2F5-4029-B673-F6B35018F5C4 Q55004289-3DC55A8E-0511-4598-96AB-D8D779433298 Q55395190-8CD9A1E7-1D73-45EC-8566-DF2158D4E180 Q55398411-BC8DC81D-B3B7-4E96-B4FC-FECED2924065 Q57162894-9079C13E-3487-467D-9D05-0BEED5637F99 Q58779270-4C33401B-091F-45BC-A782-C43C822F6442

P2860

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

http://www.wikidata.org/entity/Q45863499

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@en

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@nl

type

label

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@en

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@nl

prefLabel

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@en

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@nl

P1433

Q45863499-20B7EB8A-D832-4417-BB6E-70B5980D664D

P1476

Q45863499-9E84D79E-3BE7-4F81-94C1-11C954EC0C42

P2093

Q45863499-56B2EC22-2063-40CA-AEF5-A49E296E0431

Q45863499-574170C6-65EF-4924-92F6-2607AC3E090D

Q45863499-A091DB3D-E9BC-4935-9940-CD7D0FC0F514

P2860

Q45863499-0BCA71DD-3C60-4699-836B-EAF0BCE07A29

Q45863499-11403E92-48A3-4EAF-8254-255F8C25E619

Q45863499-116A2A2A-B442-4EDA-8AAA-D248D074CE48

Q45863499-1499C17F-A918-4351-B9E1-5C3002147D4B

Q45863499-14C5D40C-584C-4EEC-A6A9-E313A2FC7AD3

Q45863499-1B0023B4-6260-4143-826B-43925105387E

Q45863499-201CB0C8-69E6-4670-9177-DD3FFFFD11DE

Q45863499-2826AF6A-4859-4744-A45B-F23D5A227A1F

Q45863499-29F9490B-E756-431D-A821-F0C7D66AFC3F

Q45863499-2D7C8106-0662-4B98-B0EA-904F83C0BF61

P304

Q45863499-F2989FF8-3AA0-46F9-B4A3-1EA6301DC85B

P31

Q45863499-DB93445C-A83D-4257-92EF-AB73261D39A8

P356

Q45863499-73956D29-52A0-4319-BC88-DB1EE8A167FB

P433

Q45863499-627625CD-D4A8-4A20-BF4A-9334499C27B2

P478

Q45863499-A0BA704C-5034-4EDB-A267-F70B42188CE1

P50

Q45863499-93E779BA-F7A7-45F7-86B4-F43E69257063

P577

Q45863499-19116577-37EF-469D-94C8-F2F92F7BE0C1

P698

Q45863499-0F6FEE25-68A2-451D-94FD-01B328981297

P921

Q45863499-5E89E4FA-2CCB-46C0-B817-2BD4CAE20CD0

Q45863499-99F5201C-A0C8-433D-850B-26F3A19ABF56

P932

Q45863499-E127D80A-4C8D-44C5-A0E0-8D3793CBD41B

P356

P1433

European Heart Journal

P1476

Angiogenic gene therapy in cardiovascular diseases: dream or vision?

@en

P2093

Charles Bridges

http://www.w3.org/2001/XMLSchema#string

Michael G Katz

http://www.w3.org/2001/XMLSchema#string

Petra Korpisalo

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association

Gene delivery technologies for cardiac applications

Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease

Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials.

Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial

Clinical applications of angiogenic growth factors and their inhibitors.

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the K

pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia.

P304

1365-1371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHW547

http://www.w3.org/2001/XMLSchema#string

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Seppo Ylä-Herttuala

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28073865

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

5837788

http://www.w3.org/2001/XMLSchema#string